10288-36-5

Basic information

• Product Name: 2,3-dihydro-1,4-benzodioxin-5-ol
• Synonyms: 2,3-dihydro-1,4-benzodioxin-5-ol;2,3-Ethylenedioxyphenol;5-Hydroxy-1,4-benzodioxane;Einecs 233-639-0;2,3-dihydro-1,4-benzodioxin-5-ol(SALTDATA: FREE);2,3-Dihydro-benzo[1,4]dioxin-5-ol;2,3-Dihydrobenzo[b][1,4]dioxin-5-ol;1,4-Benzodioxin-5-ol,2,3-dihydro-
• CAS NO: 10288-36-5
• Molecular Formula: C₈H₈O₃
• Molecular Weight: 152.14732
• EINECS: 233-639-0
• Mol File: 10288-36-5.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 260.2°Cat760mmHg
• Flash Point: 111.2°C
• Appearance: /
• Density: 1.302g/cm³
• Vapor Pressure: 0.00765mmHg at 25°C
• Refractive Index: 1.58
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 9.72±0.20(Predicted)
• CAS DataBase Reference: 2,3-dihydro-1,4-benzodioxin-5-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-dihydro-1,4-benzodioxin-5-ol(10288-36-5)
• EPA Substance Registry System: 2,3-dihydro-1,4-benzodioxin-5-ol(10288-36-5)

Safety Data

• Hazardous Substances Data: 10288-36-5(Hazardous Substances Data)

Usage

General Description

2,3-dihydro-1,4-benzodioxin-5-ol is a chemical compound, specifically an aromatic ether and dihydrobenzodioxin. One of the most notable features is the fact that it contains two oxygen atoms bonding the two carbon atoms, forming a heterocyclic compound. Its molecular structure has a rigid construct which is associated with its exceptional stability. The mentioned compound is used in various fields in the chemical industry due to its versatility, but there is limited publicly available information about its specific uses or properties. As with any chemical, proper handling and safety measures should be followed when working with 2,3-dihydro-1,4-benzodioxin-5-ol.

InChI:InChI=1/C8H8O3/c9-6-2-1-3-7-8(6)11-5-4-10-7/h1-3,9H,4-5H2

Upstream product

• 154582-36-2 5-Cyanomethoxy-1,4-benzodioxane 
• 1710-55-0 5-methoxy-2,3-dihydrobenzo[b][1,4]dioxane 
• 106-93-4 ethylene dibromide 
• 87-66-1 2-hydroxyresorcinol 

Downstream Products

• 154582-36-2 5-Cyanomethoxy-1,4-benzodioxane 
• 42965-39-9 2,3-dihydro-1,4-benzodioxine-5,8-quinone 
• 1710-62-9 5-(2-bromoethoxy)-2,3-dihydrobenzo[b][1,4]dioxine 
• 214895-04-2 2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-butyl]-isoindole-1,3-dione 

Relevant articles and documents

Studies toward the discovery of the next generation of antidepressants. Part 2: Incorporating a 5-HT1A antagonist component into a class of serotonin reuptake inhibitors

The design and synthesis of a novel series of indole derivatives (9) having dual 5-HT transporter reuptake and 5-HT1A antagonist activity are described.

Synthesis and inhibitory activity of new ethylenedioxyquinones as analogs of coenzyme

A new series of analogs of coenzyme Q, 2,3 ethylenedioxy 5 hydroxy 6 alkyl 1,4 benzoquinones, was synthesized on the basis of the minor differences in the electronic and rotational nature between the 2,3 ethylenedioxy group and 2,3 dimethoxy groups. These differences could affect the redox potential of the 1,4 benzoquinone and, in turn, affect inhibitory activity. The 6 alkyl groups were farnesyl, phytyl, nonyl, decyl, pentadecyl, heptadecyl, and 5' (cyclohexyl)pentyl. The succinoxidase and DPNH oxidase systems of intact mitochondria from beef heart were used in tests for inhibition. The nonyl, decyl, pentadecyl, and farnesyl analogs showed inhibitions of less than 40%; and the phytyl, heptadecyl, and 5' (cyclohexyl)pentyl analogs showed inhibitions of about 50% in succinoxidase. All the analogs were less inhibitory in DPNH oxidase. 2,3 Dimethoxy 5 hydroxy 6 n pentadecyl 1,4 benzoquinone showed 91% inhibition at a concentration of 97 nmol of inhibitor/mg of mitochondrial protein, while 2,3 ethylenedioxy 5 hydroxy 6 n pentadecyl 1,4 benzoquinone exhibited only 37% inhibition at the higher concentration of 140 nmol of inhibitor/mg of mitochondrial protein in the succinoxidase system. Similarly, this 2,3 dimethoxyquinone was a more potent inhibitor in DPNH oxidase. 2,3 Dimethoxy 5 hydroxy 6 n pentadecyl 1,4 benzoquinone showed 91% inhibition at a concentration of 97 nmol of inhibitor/mg of mitochondrial protein, while 2,3 ethylenedioxy 5 hydroxy 6 n pentadecyl 1,4 benzoquinone exhibited only 37% inhibition at the higher concentration of 140 nmol of inhibitor/mg of mitochondrial protein in the succinoxidase system. Similarly, this 2,3 dimethoxyquinone was a more potent inhibitor in DPNH oxidase than the corresponding 2,3 ethylenedioxyquinone. Apparently, 2,3 dimethoxy groups are more favorable than the 2,3 ethylenedioxy group on the 5 hydroxy 6 alkyl 1,4 benzoquinone nucleus for inhibition of these two CoQ oxidases.

VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS

Pyrimidine ethers and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

Azaindole derivatives for the treatment of depression

Compounds useful in the treatment of diseases affected by disorders of the serotonin-affected neurological systems, such as depression and anxiety, are provided having the following formula: wherein: R1and R2form a carbocyclic ring of 5 to 7 carbon atoms, wherein said ring may be saturated or unsaturated and may contain one or more heteroatoms; and X is independently hydrogen, cyano, carbamoyl, halogen or alkoxy; or pharmaceutically acceptable salts thereof.